Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer

William M. MerrittUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USAYvonne G. LinUniversity of Texas M.D. Anderson Cancer Center, HoustonLiz Y. HanUniversity of Texas M.D. Anderson Cancer Center, HoustonAparna A. KamatUniversity of Texas M.D. Anderson Cancer Center, HoustonWhitney A. SpannuthUniversity of Texas M.D. Anderson Cancer Center, HoustonRosemarie SchmandtUniversity of Texas M.D. Anderson Cancer Center, HoustonDiana L. UrbauerUniversity of Texas M.D. Anderson Cancer Center, HoustonL PennacchioU.S. Department of Energy Joint Genome Institute, Walnut Creek, CAJan‐Fang ChengLawrence Berkeley National Laboratory, Berkeley, CAAlpa M. NickUniversity of Texas M.D. Anderson Cancer Center, HoustonMichael T. DeaversUniversity of Texas M.D. Anderson Cancer Center, HoustonAlexandra A. Mourad-ZeidanUniversity of Texas M.D. Anderson Cancer Center, HoustonHua WangUniversity of Texas M.D. Anderson Cancer Center, HoustonPeter P. MuellerUniversity of Texas M.D. Anderson Cancer Center, HoustonMarc E. LenburgBoston University School of MedicineJoe W. GrayLawrence Berkeley National Laboratory, Berkeley, CASamuel C. MokBrigham and Women's HospitalMichael J. BirrerCenter for Cancer Research, Bethesda, MDGabriel Lopez‐BeresteinUniversity of Texas M.D. Anderson Cancer Center, HoustonRobert L. ColemanUniversity of Texas M.D. Anderson Cancer Center, HoustonMenashe Bar‐EliUniversity of Texas M.D. Anderson Cancer Center, HoustonAnil K. SoodUniversity of Texas M.D. Anderson Cancer Center, Houston
2008en
ABI

Annotatsiya

BACKGROUND: We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer. METHODS: We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase-polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung cancer. Mutational analyses of genomic DNA from the Dicer and Drosha genes were performed in a subgroup of ovarian-cancer specimens. Dicer-dependent functional assays were performed by means of in vitro transfection with small interfering RNA (siRNA) and short hairpin RNA (shRNA). RESULTS: Levels of Dicer and Drosha mRNA correlated with the levels of expression of the corresponding protein and were decreased in 60% and 51% of ovarian-cancer specimens, respectively. Low Dicer expression was significantly associated with advanced tumor stage (P=0.007), and low Drosha expression with suboptimal surgical cytoreduction (P=0.02). Cancer specimens with both high Dicer expression and high Drosha expression were associated with increased median survival (>11 years, vs. 2.66 years for other subgroups; P<0.001). We found three independent predictors of reduced disease-specific survival in multivariate analyses: low Dicer expression (hazard ratio, 2.10; P=0.02), high-grade histologic features (hazard ratio, 2.46; P=0.03), and poor response to chemotherapy (hazard ratio, 3.95; P<0.001). Poor clinical outcomes among patients with low Dicer expression were validated in additional cohorts of patients. Rare missense mutations were found in the Dicer and Drosha genes, but their presence or absence did not correlate with the level of expression. Functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. CONCLUSIONS: Our findings indicate that levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba